At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 3,591 enrolled
Drug / intervention
theraputic heparin +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Adaptive, Randomized Controlled Platform Trial of the Safety and Efficacy of Antithrombotic and Additional Strategies in Hospitalized Adults With COVID-19
In Brief
A Phase 4 clinical trial evaluating theraputic heparin, prophylactic heparin, and 3 other interventions for Covid19. Completed, enrolled 3,591 participants across 101 sites in 4 countries.
Detailed Summary
This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCovid19
CountriesBrazil, Italy, Spain, United States
CollaboratorsNational Heart, Lung, and Blood Institute (NHLBI)
Timeline
Phase 4CompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartSep 2020
Primary CompletionAug 2023
Study CompletionJan 2024
TodayJul 2026
First PostedAug 10, 2020
Enrollment StartSep 4, 2020
Primary CompletionAug 31, 2023
Study CompletionJan 26, 2024
TodayJul 2, 2026
Enrollment to primary: 3.0 yearsPosted 5.9 years ago
Interventions
theraputic heparindrug
increased dose of heparin above standard of care.
prophylactic heparindrug
standard of care dose of heparin
P2Y12drug
added P2Y12 inhibitor
Crizanlizumab Injectiondrug
crizanlizumab injection
SGLT2 inhibitordrug
sglt2 inhibitor